Harmony Biosciences Holdings, Inc.

Total Valuation

Harmony Biosciences Holdings, Inc. carries a market capitalization of 2.45B, placing it among publicly traded companies globally. Its enterprise value stands at 1.60B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Harmony Biosciences Holdings, Inc. currently has 58.12M shares outstanding.

Valuation Ratios

Harmony Biosciences Holdings, Inc. trades at a trailing price-to-earnings ratio of 11.60. The price-to-sales ratio is 2.19, and the price-to-book ratio stands at 2.12.

Enterprise Valuation

On an enterprise value basis, Harmony Biosciences Holdings, Inc. trades at an EV/EBITDA multiple of 6.26 and an EV/FCF ratio of 4.39. The EV/Sales ratio of 1.67 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 6.95 provides insight into valuation relative to core operating earnings.

Financial Position

Harmony Biosciences Holdings, Inc. maintains a current ratio of 3.48, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 15.41, indicating elevated leverage, while an interest coverage ratio of 19.00 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Harmony Biosciences Holdings, Inc. posts a return on equity of 20.46 and a return on invested capital of 16.52.

Taxes

Over the trailing twelve months, Harmony Biosciences Holdings, Inc. has paid 59.93M in income taxes, reflecting an effective tax rate of 24.85.

Stock Price Statistics

Harmony Biosciences Holdings, Inc.'s stock has gained approximately 17.39372% over the past 52 weeks. The 50-day moving average sits at 37.40, while the 200-day moving average is 34.19.

Income Statement

Over the trailing twelve months, Harmony Biosciences Holdings, Inc. generated 959.90M in revenue and converted that into 181.27M in net income, yielding earnings per share of 3.09. EBITDA reached 255.99M, while operating income came in at 230.65M.

Balance Sheet

Harmony Biosciences Holdings, Inc. holds 667.79M in cash and equivalents against 153.96M in total debt, resulting in a net debt position of -395.81M. Total book value stands at 999.24M, with working capital of 580.26M providing operational flexibility.

Cash Flow

Harmony Biosciences Holdings, Inc. produced 355.08M in operating cash flow over the past twelve months. After subtracting -178,000.00 in capital expenditures, free cash flow totaled 354.90M - equivalent to 6.15 per share.

Margins

Harmony Biosciences Holdings, Inc. operates with a gross margin of 75.42, reflecting its pricing power and cost economics. The operating margin of 24.03 and net profit margin of 18.88 provide insight into operational efficiency.

Dividends & Yields

Scores

Harmony Biosciences Holdings, Inc. posts an Altman Z-Score of 5.55, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.